ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
ARCS has launched a comprehensive Core Competency Framework tailored for the Medtech and Pharmaceutical sectors. The framework is designed to ensure members possess the specialised knowledge and skills required to excel within the sector, aiming to set benchmark for professional excellence.
“Our Core Competency Framework is a milestone in our journey to elevate professional standards for those working within the sector,” said Dr Boyle,. “It provides a structured pathway for continuous professional development common to all sectorial occupations and ensures our members are equipped with the expertise needed to meet professional demands.”
Expanding upon the Core Competency Framework, ARCS has also established international partnerships with the Association of Clinical Research Professionals (ACRP), the Regulatory Affairs Professionals Society (RAPS), and the International Society of Pharmacovigilance (ISoP) to recognise their occupation specific competency frameworks and accreditation standards. These partnerships aim to facilitate the creation of professional training pathways aligned with globally recognised best practice for sectorial occupations.
“Our alliances with ACRP, RAPS, and ISoP are pivotal in offering our members access to globally recognised professional pathways and raising the standard of Australian professionals through globally recognised professional accreditation,” said Dr Boyle.
“These collaborations help raise the bar and advance the professional standing of Australian Medtech and Pharmaceutical professionals on a global playing field.”
In recognition of professional excellence, ARCS will now issue postnominals to professional members based on their expertise. The aim of this designation is to underscore a member’s commitment to the highest standards of practice and their specialised expertise.
“The initiatives we are announcing today mark a new era for ARCS,” Dr Boyle concluded. “By establishing a robust competency framework, recognising professional excellence through postnominals, fostering international collaborations, and honouring our distinguished Fellows, we are setting a new standard for professionalism within the Australian Medtech and Pharmaceutical sectors.”
-
Study on digital tool for pharmacists in aged care
In March 2022, the Australia government announced $350 million of funding over 4 years to employ on-site pharmacists in residential aged care, starting July 2023. In April 2023, the government made changes to the proposed on-site pharmacists, where the new program will now be delivered by and through community pharmacies. Regardless of how the model will be implemented, the goal remains the same – to improve quality use of medicines and medicines safety for aged care residents.
-
Global MedTech company brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
